Market access strategy, HTA, and health economics.

Our aim is to create value. We deliver highly specialised work, delivered with a seamless, cut-to-the-chase approach: we get to the point, we give you honest advice, and we provide pragmatic and solution-oriented consulting.

1 Market Access Strategy

There is rarely a perfect solution in market access. There is always a best possible one, and we help you find it.

There is no one-size-fits-all approach. Different medicines, different indications, different evidence, different landscapes. All of it shapes what the optimal strategy looks like.

We understand these nuances and build strategies that factor in local requirements, the specifics of your medicine or device, the evidence, the positioning, and the moving pricing and reimbursement landscape, so you can choose an option that actually fits.

And with more than 10 years in this field, we have the cases to prove it.

Click an area to open it

Landscape analyses Do you have the full picture of the market, and where the hurdles sit?

Pricing & positioning Uncertain on price, and which population to target first?

Market access strategy Is the strategy aligned with payer expectations?

Early value assessment Have you found every value driver, and the outcomes that matter?

2 Health Technology Assessment

The quality of your HTA submission decides how likely access success is.

Guidelines for HTA submissions are often strict, but a strict guideline does not make the result a foregone conclusion. We help you think past the template: to capture relevant elements of value and give the value story a clear red thread.

With 10+ years in Nordic HTA submissions, this is our specialty. We know what to consider, how to weigh it, and how to present it.

Click a capability to open it

Local validation Tested the way the local assessor will read it.

National & pan-Nordic HTA dossiers One value core, adapted to each system.

Payer insights We have sat on their side of the table.

HTA strategy, early model to submission A red thread from first model to final file.

3 Health Economics

Why NHTA is your partner for showing the value of your product.

In cost-effectiveness markets, health economics plays a pivotal role in reimbursement decisions.

To pass assessor review a health economic model needs to be methodologically rigorous but it must also showcase the true value of your product. Striking this balance is what we Excel at.

We are guided by our backgrounds in HTA bodies, payer organisations and the pharma and medtech industry. Combine that with 8+ years and 200+ bespoke models and adaptations, and you have a rare recipe.

But first, we need to understand your needs and objectives to find the right solution for you.

Click a capability to open it

Model conceptualisation & development Built from the structure up, not a black box.

Local adaptation of existing models Keep the global structure, fix the local fit.

Payer engagement tools Value a payer can explore in the room.

Early modelling Numbers that shape strategy, not just the file.

Evidence & analytics

Underneath all of it: evidence that holds up.

Strategy, HTA and health economics only work if the evidence behind them survives scrutiny. Here are five places a modern submission gets stuck, and how we handle each.

Let's get to the point

Tell us where you are headed, and we will tell you the best possible route to access.

Strategy, HTA and health economics, under one roof, with the people who have done it for over a decade. The first conversation is the fastest way to see if we fit.